Abstract
Aims: The HeartWare VAD, third-generation implantable VAD, includes an axial pump integrated into the device. Despite its advantages, the rate of thrombus formation and of thrombo-embolic events are not negligible. The therapeutic options are few; thrombolytic therapy with the risks of recurrence and bleeding, and surgical device exchange associating with the problems of an urgent redo procedure. Actually, there is no recommendation concerning the management of pump thrombosis. The aim of the study was to report the Bad Oeynhausen experience concerning the management of LVAD HeartWare thrombus. We related 7 cases of HeartWare thrombosis which were treated by the two strategy systemic thrombolysis and pump exchange.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
